(UroToday.com) As a portion of the European Society for Medical Oncology (ESMO) Annual Congress, an Educational Session focused on precision management of patients with prostate cancer was held. In this context, Dr. Jean-Emmanuel Bibault discussed the role of artificial intelligence to guide prostate cancer treatment.
(UroToday.com) In this presentation, Dr. Enrique Grande discussed the results of the GETUG/AFU VESPER V05 Phase III Trial and the Phase II trial of pembrolizumab plus sEphB4-HSA in metastatic urothelial carcinoma (UC). These two studies led to exciting results with the potential to impact practice for patients with urothelial carcinoma in the future.
(UroToday.com) As a portion of the European Society for Medical Oncology (ESMO) Annual Congress, an Educational Session focused on personalized care in genitourinary cancers was held. In this context, Dr. Turajlic discussed the role of biomarkers in kidney cancer. She began by highlighting the profound need for biomarkers in the management of patients with renal cell […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 annual meeting’s non-prostate cancer preferred paper session included a presentation by Dr. Thomas Powles discussing the first phase 2 results from the NORSE study assessing erdafitinib or erdafitinib plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma and fibroblast growth factor receptor (FGFR) alterations. First-line […]
(UroToday.com) The European Society of Medical Oncology (ESMO) 2021 meeting’s proffered paper session for non-prostate genitourinary tumors included a discussant presentation by Dr. Srikala Sridhar of the phase 2 NORSE trial assessing erdafitinib or erdafitinib plus cetrelimab for patients with metastatic or locally advanced urothelial carcinoma and fibroblast growth factor receptor (FGFR) alterations. Dr. Sridhar started […]
(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Madan provided an assessment of a semi-automated method of assessing Sodium Fluoride (NaF) PET using a novel technology. This is particularly relevant given that current and emerging PET platforms are enhancing clinicians’ ability to evaluate metastatic lesions in mCRPC.
(UroToday.com) In this presentation, Dr. Christian Pfister presented results of the GETUG/AFU VESPER V05 phase III clinical trial, which compared dose-dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin (ddMVAC) versus Gemcitabine and Cisplatin (GC) as perioperative chemotherapy for patients with muscle-invasive bladder cancer (MIBC). The standard of care for MIBC in 2021 is radical cystectomy with perioperative chemotherapy, […]
(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Stephane Oudard presented data on patient-reported health-related quality of life (HRQoL) in the context of the ACIS trial (NCT02257736). This phase III trial randomized patients with metastatic castration resistant prostate cancer (mCRPC) to receive either abiraterone acetate and prednisone […]
(UroToday.com) As a portion of the European Society for Medical Oncology (ESMO) Annual Congress, an Educational Session focused on the management of patients with node-positive locally advanced prostate cancer was held. In this context, Dr. Chris Parker discussed the role of radiotherapy for these patients. He began by emphasizing that there are no randomized controlled trials […]
(UroToday.com) In the on-demand poster session of the European Society for Medical Oncology (ESMO) Annual Congress, Dr. Holger Palmedo reported results of the PARABO cohort (NCT02398526), a prospective, observational, noninterventional, single-arm study evaluating pain efficacy in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with Radium-223 in German real-life nuclear medicine settings.
